Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

Meritxell Nomdedeu, Xavier Calvo, Arturo Pereira, Anna Carrió, Francesc Solé, Elisa Luño, José Cervera, Teresa Vallespí, Concha Muñoz, Cándida Gómez, Amparo Arias, Esperanza Such, Guillermo Sanz, Javier Grau, Andrés Insunza, María José Calasanz, María Teresa Ardanaz, Jesús María Hernández-Rivas, Gemma Azaceta, Sara ÁlvarezJoaquín Sánchez, María Luisa Martín, Joan Bargay, Valle Gómez, Carlos Javier Cervero, María José Allegue, Rosa Collado, Elías Campo, Jordi Esteve, Benet Nomdedeu, Dolors Costa

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2015 Wiley Periodicals, Inc. Chromosomal translocations are rare in the myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). With the exception of t(3q), translocations are not explicitly considered in the cytogenetic classification of the IPSS-R and their impact on disease progression and patient survival is unknown. The present study was aimed at determining the prognostic impact of translocations in the context of the cytogenetic classification of the IPSS-R. We evaluated 1,653 patients from the Spanish Registry of MDS diagnosed with MDS or CMML and an abnormal karyotype by conventional cytogenetic analysis. Translocations were identified in 168 patients (T group). Compared with the 1,485 patients with abnormal karyotype without translocations (non-T group), the T group had a larger proportion of patients with refractory anemia with excess of blasts and higher scores in both the cytogenetic and global IPSS-R. Translocations were associated with a significantly shorter survival and higher incidence of transformation into AML at univariate analysis but both features disapeared after multivariate adjustment for the IPSS-R cytogenetic category. Patients with single or double translocations other than t(3q) had an outcome similar to those in the non-T group in the intermediate cytogenetic risk category of the IPSS-R. In conclusion, the presence of translocations identifies a subgroup of MDS/CMML patients with a more aggressive clinical presentation that can be explained by a higher incidence of complex karyotypes. Single or double translocations other than t(3q) should be explicitly considered into the intermediate risk category of cytogenetic IPSS-R classification.
Original languageEnglish
Pages (from-to)322-327
JournalGenes Chromosomes and Cancer
Volume55
Issue number4
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint Dive into the research topics of 'Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this